Showing 850 results
-
Media Release /-- Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone(1)-- Study shows everolimus significantly…
-
Media Release /- Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies(1)- Evidence indicates that QTI571 targets an…
-
Media Release /- Study met primary endpoint of kidney tumor response rate with 42% of patients on everolimus experiencing a response versus 0% on placebo(1)- Kidney tumors are present in up to 80% of patients with…
-
Media Release /- Trial shows Exjade, an iron chelator, is significantly better than placebo at reducing liver iron concentration in patients with NTDT- Non-transfusion-dependent thalassemia (NTDT) is a genetic…
-
Media Release /- ENESTcmr data show 23% of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11% who continued on Gleevec(1)- Three-year ENESTnd data show 32% of…
-
Media Release /- Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty[2],[3]- The new pivotal Phase III data also showed…
-
Media Release /Now available in US pharmacies, Hecoria (tacrolimus) capsules are approved for the prevention of organ rejection in certain kidney and liver transplant patientsHecoria, a branded generic, complements…
-
Media Release /- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant…
-
Media Release /- Company to resolve wage and hour claims with one-time payment of up to 99 million dollars for eligible class members- Novartis Pharmaceuticals Corporation remains committed to compensate all…
-
Media Release /• In the trial, patients on Exelon Patch 13.3 mg/24 h showed less functional decline vs. 9.5 mg/24 h patch in mild to moderate Alzheimer’s disease• Numerical trend toward cognitive efficacy was seen…
